MustGrow Announces Grant of RSUs and DSUs
Rhea-AI Summary
MustGrow Biologics (OTCQB: MGROF) announced the grant of 1,660,315 deferred share units (DSUs) and restricted share units (RSUs) to directors, officers, and consultants, effective September 25, 2025. The grants were made under the company's Omnibus Equity Incentive Plan.
The DSUs will vest upon the holder's departure from their role at the company or its affiliates. Upon settlement, DSU holders will receive either one common share or an equivalent cash payment at the company's discretion.
Positive
- None.
Negative
- None.
Saskatoon, Saskatchewan--(Newsfile Corp. - September 26, 2025) - MustGrow Biologics Corp. (TSXV: MGRO) (OTCQB: MGROF) (FSE: 0C0) (the "Company" or "MustGrow") today announced that the board of directors of the Company authorized and approved the grant of a total of 1,660,315 deferred share units ("DSUs") and restricted share units ("RSUs") to certain directors, officers, and consultants of the Company, effective September 25, 2025. This grants of DSUs and RSUs are made pursuant to the Company's Omnibus Equity Incentive Plan (the "Plan").
The DSUs will vest when the holder ceases to be a director, officer or employee of the Company or any of its affiliates, as applicable. On settlement, each DSU will entitle the holder to recive to receive one common share in the capital of the Company or a cash payment equivalent thereof at the discretion of the Company.
---------
About MustGrow
MustGrow Biologics Corp. is a fully-integrated provider of innovative biological and regenerative agriculture solutions designed to support sustainable farming. The Company's proprietary and third-party product lines offer eco-friendly alternatives to restricted or banned synthetic chemicals and fertilizers. In North America, MustGrow offers a portfolio of third-party crop nutrition solutions, including micronutrients, nitrogen stabilizers, biostimulants, adjuvants and foliar products. These products are synergistically distributed alongside MustGrow's wholly-owned proprietary products and technologies that are derived from mustard and developed into organic biocontrol and biofertility products to help replace banned or restricted synthetic chemicals and fertilizers. Outside of North America, MustGrow is focused on collaborating with agriculture companies, such as Bayer AG in Europe, the Middle East and Africa, to commercialize MustGrow's wholly-owned proprietary products and technologies. The Company is dedicated to driving shareholder value through the commercialization and expansion of its intellectual property portfolio of approximately 109 patents that are currently issued and pending, and the sales and distribution of its proprietary and third-party product lines through NexusBioAg. MustGrow is a publicly traded company (TSXV: MGRO) and has approximately 58.9 million common shares issued and outstanding and 69.1 million shares fully diluted. For further details, please visit www.mustgrow.ca.
Contact Information
Corey Giasson
Director & CEO
Phone: +1-306-668-2652
info@mustgrow.ca
This release does not constitute an offer for sale of, nor a solicitation for offers to buy, any securities in the United States.
Neither the TSXV, nor their Regulation Services Provider (as that term is defined in the policies of the TSXV), nor the OTC Markets has approved the contents of this release or accepts responsibility for the adequacy or accuracy of this release.
© 2024 MustGrow Biologics Corp. All rights reserved.
To view the source version of this press release, please visit https://www.newsfilecorp.com/release/268059
FAQ
How many DSUs and RSUs did MustGrow Biologics (MGROF) grant in September 2025?
When do the MustGrow Biologics DSUs vest?
What will DSU holders receive upon settlement at MustGrow Biologics?
Under which plan were the MustGrow Biologics DSUs and RSUs granted?
